In vivo models of human immunodeficiency virus persistence and cure strategies

CC Nixon, M Mavigner, G Silvestri… - The Journal of …, 2017 - academic.oup.com
CC Nixon, M Mavigner, G Silvestri, JV Garcia
The Journal of infectious diseases, 2017academic.oup.com
Current HIV therapy is not curative regardless of how soon after infection it is initiated or how
long it is administered, and therapy interruption almost invariably results in robust viral
rebound. Human immunodeficiency virus persistence is therefore the major obstacle to a
cure for AIDS. The testing and implementation of novel yet unproven approaches to HIV
eradication that could compromise the health status of HIV-infected individuals might not be
ethically warranted. Therefore, adequate in vitro and in vivo evidence of efficacy is needed …
Abstract
Current HIV therapy is not curative regardless of how soon after infection it is initiated or how long it is administered, and therapy interruption almost invariably results in robust viral rebound. Human immunodeficiency virus persistence is therefore the major obstacle to a cure for AIDS. The testing and implementation of novel yet unproven approaches to HIV eradication that could compromise the health status of HIV-infected individuals might not be ethically warranted. Therefore, adequate in vitro and in vivo evidence of efficacy is needed to facilitate the clinical implementation of promising strategies for an HIV cure. Animal models of HIV infection have a strong and well-documented history of bridging the gap between laboratory discoveries and eventual clinical implementation. More recently, animal models have been developed and implemented for the in vivo evaluation of novel HIV cure strategies. In this article, we review the recent progress in this rapidly moving area of research, focusing on the two most promising model systems: humanized mice and nonhuman primates.
Oxford University Press